BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191202
DTEND;VALUE=DATE:20191205
DTSTAMP:20260515T032611
CREATED:20190815T095332Z
LAST-MODIFIED:20190815T095403Z
UID:21972-1575244800-1575503999@www.pharmajournalist.com
SUMMARY:2nd Annual RNA Targeted Drug Discovery
DESCRIPTION:At a time when the previously untapped drug discovery opportunity promised within RNA opens up\, the 2nd RNA- Targeted Drug Discovery Summit returns to reunite the leading minds from large pharma\, innovative biotech and KOLs of academia to discuss unique discovery and development challenges that must be overcome for novel RNA targeted small molecule therapeutics to achieve their seemingly limitless potential. \n \nFor the 2nd year\, network with the KOLs and RNA pioneers\, to gain a comprehensive understanding on how to translate the first generation of RNA targeted small molecules into the clinic\, stimulate the discussion of successfully targeting RNA via interfering with RNA-protein interactions and seize the therapeutic opportunity in hand by re-defining the undruggable nature of RNA. \nDownload the Full Event Guide. \nWith 22 world-class speakers sharing their latest findings\, join those who are re-defining the undruggable nature of RNA: \n\nKevin Weeks\, Founder of Ribometrix; Professor of Chemistrym\, University of North Carolina\nFrank Slack\, Co-Founder of Twentyeight-Seven Therapeutics; Professor\, BIDMC\nKathryn McCabe\, Sr. Director of Business Development\, Eli Lilly\nMartin Pettersson\, Research Fellow\, Pfizer\nChristopher Barbieri\, Senior Investigator\, Bristol-Myers Squibb\nJennifer Petter\, Founder & CSO\, Arrakis Therapeutics\nYochi Slonim\, Co-founder & CEO\, Anima Biotech\nGerhard Mueller\, CSO\, Gotham Therapeutics\nChristopher R. Trotta\, VP\, Biology\, PTC Therapeutics\n\nThis is only some of the senior experts confirmed to present – check out the full speaker faculty and case studies here. \nOnce again join your RNA community at this translational and industry dedicated event focused on optimizing target validation\, improving drug-like properties & accelerating the translation of selective and bioactive RNA targeted small molecule therapeutics into human clinical trials. \nCheck out the official event guide for full speaker details or if you’re ready to register\, secure your place here.
URL:https://www.pharmajournalist.com/event/2nd-annual-rna-targeted-drug-discovery/
LOCATION:The Westin Copley Place\, 10 Huntington Avenue\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191203
DTEND;VALUE=DATE:20191206
DTSTAMP:20260515T032611
CREATED:20190909T090526Z
LAST-MODIFIED:20190909T101000Z
UID:22341-1575331200-1575590399@www.pharmajournalist.com
SUMMARY:Oncolytic Virotherapy Summit 2019
DESCRIPTION:Now in its 5th year\, the Oncolytic Virotherapy Summit is the industry’s definitive guide to turning viral vehicles into clinically effective therapeutics across oncology indications. With 3 days of in-depth cutting-edge case studies and the highest calibre of industry discussions\, The OV Summit will provide the roadmap to oncolytic virotherapy success. \nHear from pharma and biotech companies of all sizes\, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities. Discover the development of oncolytic viruses that engage the immune system for long-term treatment and management of cancers. \nTo learn more and to register online\, visit: http://bit.ly/2kmZGQh
URL:https://www.pharmajournalist.com/event/oncolytic-virotherapy-summit-2019/
LOCATION:Westin Boston Waterfront\, 425 Summer St\, Boston\, MA 02210
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191203
DTEND;VALUE=DATE:20191206
DTSTAMP:20260515T032611
CREATED:20191101T093844Z
LAST-MODIFIED:20191101T093844Z
UID:23150-1575331200-1575590399@www.pharmajournalist.com
SUMMARY:3rd Microbiome Movement – Gut-Brain Axis Summit
DESCRIPTION:The 3rd Microbiome Movement – Gut-Brain Axis Summit is returning to Boston this December and will unite pioneering industry and academic researchers to establish the mechanistic pathways contributing to neurological disorder manifestation\, overcome the scientific and translational challenges of working in the gut-brain setting and capitalize on this therapeutic opportunity. \n \nThis meeting provides the opportunity for you to: \n\nDiscover pioneering preclinical data implicating metabolic\, immune-mediated and enteroendocrine pathways in CNS disease development\nExplore translational approaches that are moving microbiome gut-brain axis science from association to causation\nLearn about critical considerations for microbiome clinical trials in the neurological and mental health setting to inform symptom and treatment management\nRealize the potential of microbial profiles as a biomarker for patient stratification to maximize the efficacy of already existing drugs for neurological disease\nUncover the relatively untapped commercial opportunity held by nutritional and therapeutic products for neurological and mental health\n\nThere is no question that the early market activity in the microbiome gut-brain axis space is critical in shaping its success. Join us to discover the microbiome science contributing to neurological disease and develop the next generation of microbiome-targeted products for improved neurological and mental health outcomes. \nFind out more here: https://ter.li/t9gsy7
URL:https://www.pharmajournalist.com/event/3rd-microbiome-movement-gut-brain-axis-summit/
LOCATION:Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:katie.jacobs@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191204
DTEND;VALUE=DATE:20191206
DTSTAMP:20260515T032611
CREATED:20190410T071442Z
LAST-MODIFIED:20191008T060245Z
UID:20275-1575417600-1575590399@www.pharmajournalist.com
SUMMARY:HR Life Sciences
DESCRIPTION:With the rapid rise of digital technology and shifts within the larger healthcare industry\, the need to find new talent that can drive innovation has never been more critical. HR Life Sciences is specifically designed for senior HR professionals at the nation’s leading Pharmaceutical\, Biotech and Medical Device companies. You’ll discover the tools\, insights\, innovations\, and cutting-edge solutions needed to evolve your hiring strategies in a rapidly changing life science industry. Register now with code PHARMAJ20 and receive a 20% discount. \n \nAt HR Life Sciences\, you’ll learn how to: \n\nRefine your talent sourcing to meet shrinking\, highly competitive talent pools\nRetain and develop top talent in an ever-changing market full of mergers & acquisitions\nKeep up with new and emerging employee engagement & development trends\nStay ahead of the curve with new HR technologies and tools suited to your workforce\nMaintain HR’s position as a visible business partner & thought-leader
URL:https://www.pharmajournalist.com/event/hr-life-sciences/
LOCATION:San Diego\, CA
ORGANIZER;CN="Worldwide Business Research":MAILTO:hrlifesciences@wbresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191204
DTEND;VALUE=DATE:20191207
DTSTAMP:20260515T032611
CREATED:20190930T095204Z
LAST-MODIFIED:20190930T104919Z
UID:22646-1575417600-1575676799@www.pharmajournalist.com
SUMMARY:8th annual PREDiCT: Tumour Models London
DESCRIPTION:The 8th annual PREDiCT: Tumour Models London Summit will return this December with a new speaker faculty to help you benchmark your oncology model selection strategy and target validation. With the rise of immuno-oncology\, model requirements\, target validation and the importance of tumour micro-environment are key to clinical success. The 3-days summit will provide you with real world data from a selected model experts\, including Merck\, MedImmune\, Takeda\, Roche\, AstraZeneca and more for practical insights. \nTo learn more about 8th annual PREDiCT: Tumour Models London and to register online\, visit https://ter.li/6ge5rc
URL:https://www.pharmajournalist.com/event/8th-annual-predict-tumour-models-london/
LOCATION:London\, UK\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191205
DTEND;VALUE=DATE:20191207
DTSTAMP:20260515T032611
CREATED:20190531T111302Z
LAST-MODIFIED:20190614T081716Z
UID:21011-1575504000-1575676799@www.pharmajournalist.com
SUMMARY:SMi’s Inaugural Conference: Respiratory Drug Delivery 2019
DESCRIPTION:SMi are pleased to announce the launch of the Respiratory Drug Delivery conference as part of the newly branded Asthma and COPD series\, which will be held in London on the 5th – 6th December 2019. \n \nWith the rising prevalence of respiratory disease such as Asthma\, cystic fibrosis and COPD\, this group of diseases are now amongst the leading cause of death\, affecting over 500 million adults and children worldwide. Lung cancer now accounts for over 50% of all respiratory disease related deaths in Europe\, yet little work is being done to reduce this high mortality rate. \nOpportunities for drug development has effectively resulted in the global pulmonary and respiratory drug delivery market expecting to reach 64 billion USD (6.7% CAGR) by 2025. However\, the unmet medical needs of respiratory diseases sufferers remain. \nJoin us this year as SMi aim to bring together clinical researchers\, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments that adhere to patient’s needs\, analysing the success of digital media devices and connective health technology in aiding the diagnosis of severe asthma and COPD. This year will also investigate the developing issues surrounding pulmonary and nasal combination product design. \nBenefits of attending: \n\nAssessing how to transform disease management through drug combinations\, devices and inhaled biological treatments\nEvaluating respiratory device design development and novel technologies such as nanoparticle-based drug delivery\nExploring digital connective inhalation to improve patient centricity\nReviewing the challenges around the pricing and reimbursement of respiratory drug products\n\nView the full agenda online: www.respiratorydrugdelivery.com/pharmajwl \nEarly bird rates: \n\nBOOK BY 28TH JUNE AND SAVE £300\nBOOK BY 30TH SEPTEMBER AND SAVE £100\n\nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #SMirespiratory\nLinkedIn: follow our company page – search ‘SMi Pharma’ \nContact \n+44 (0) 20 7827 6088\nhsidhu@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/respiratory-drug-delivery-2019/
LOCATION:Holiday Inn Kensington Forum\, 97 Cromwell Road\, London\, SW7 4DN\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191210
DTEND;VALUE=DATE:20191212
DTSTAMP:20260515T032611
CREATED:20190909T102201Z
LAST-MODIFIED:20190909T123702Z
UID:22345-1575936000-1576108799@www.pharmajournalist.com
SUMMARY:BioFIT 2019
DESCRIPTION:EARLY-STAGE INNOVATIONS | ACADEMIA-INDUSTRY COLLABORATIONS | TECHNOLOGY TRANSFER | SEED INVESTMENT \nWith the highest attending rate of TTOs\, research institutes and academia together with big pharma\, emerging and small biotech\, diagnostics companies\, pre-seed / seed / Series A investors\, BioFIT is the leading partnering event in Europe for technology transfer\, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed\, seed and Series A investment in Life Sciences. \nWHY ATTEND BIOFIT? \nOut of 1\,000 BioFIT attendees\, 1\,000 deals have been generated. The breakdown in terms of nature of deals is the following: \n\n35% of collaborative research projects\n30% of licensing deals\n15% of equity investment deals\n20% of services deals\n\nEstimate based on the measurement of 2015 and 2016 delegates’ outcomes \n  \nKEY FIGURES: \n\n1\,300+ delegates\n800+ organisations\n35+ countries represented\n1\,000 deals generated in 2017\n\nINSIDE THE EVENT: \n\nA business convention with pre-qualified one-to-one meetings\n Identification of would-be CEOs\nConferences and roundtable discussions\nOral presentations of start-ups \, licensing opportunities stemming from academia \, service presentations\nAn exhibition area\nInformal networking evenings\n\nPlease check out the different participants’ lists of the previous editions\, as well as the list of this year’s edition >>here<<.\n2018 Final programme\n2019 Preliminary programme \nPlease feel free to widely share this document with your colleagues\, network\, partners… \nBE PART OF THE EVENT: \n\nRegister now\nBook your booth now\n\nWebsite: www.biofit-event.com\nTwitter: @BIOFIT_EVENT
URL:https://www.pharmajournalist.com/event/biofit-2019/
LOCATION:MARSEILLE CHANOT\, PALAIS DES CONGRÈS ET DES EXPOSITIONS Rond Point du Prado 13008 Marseille – FRANCE
ORGANIZER;CN="Eurasant%C3%A9":MAILTO:msatola@eurasante.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191210
DTEND;VALUE=DATE:20191213
DTSTAMP:20260515T032611
CREATED:20191101T123339Z
LAST-MODIFIED:20191101T124951Z
UID:23209-1575936000-1576195199@www.pharmajournalist.com
SUMMARY:Cell Therapy Analytical Development Summit
DESCRIPTION:The explosion in cell therapy development companies has fueled a need to develop well-characterized clinical products which has resulted in the call for robust and validated analytical assays now being louder and more important than ever before. \nThe inaugural Cell Therapy Analytical Development Summit brings you the leaders in CMC\, analytics and process development to create standardized and automated analytical techniques and technologies for improved therapeutic characterization at scale. \nJoin over 100 of the world’s experts as we discuss how to navigate a murky regulatory landscape\, robustly validate assays and advance the characterization of CAR-T and TCR cell therapy analytics to ensure safe\, consistent and quality cell therapy products. \n \nGet involved this December to: \n\nAddress the need to fully understand the mechanism of action of a cell therapy to develop representative potency assays\nAssess methods to develop functional assays suitable for routine and timely testing to overcome operational constraints\nExplore ways to develop non-destructive and non-invasive in-line analytics\nDiscuss current techniques being developed to standardize flow cytometry and explores ways to overcome batch effects\nHighlight sources of variability in cell counting measurement such as environmental\, procedural\, analytical and instrumental\, and techniques to minimize variability\n\nWhy do experts attend our cell therapy summits? \n“Moments where we can come together with passionate individuals and companies who are focused on advancing cancer care are inspiring\, and the Cell Therapy Summit is no different. We are energized by the discussions about cell therapy and its potential applications for bringing new therapies to patients in need.”\n– Novartis \n“This is a best in class and top summit in the cell therapy area which is an invaluable asset to both industries and academia.”\n– University of Pennsylvania \nJoin us to ensure safe\, consistent and quality cell therapy development with novel\, scalable and automated analytical development assays. \nTo know more about Cell Therapy Analytical Development Summit click here
URL:https://www.pharmajournalist.com/event/cell-therapy-analytical-development-summit/
LOCATION:Revere Hotel Boston Common  200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR